Fracture risks of antidepressants

Area of Science:

• Pharmacology
• Geriatric Medicine
• Public Health

Background:

• Antidepressants are widely prescribed medications for mood disorders.
• Fracture risk is a significant concern, particularly in aging populations.
• Understanding medication-specific risks is crucial for patient safety.

Purpose of the Study:

• To investigate the association between different classes of antidepressants and fracture risk.
• To differentiate fracture risk profiles among tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and other antidepressant groups.
• To examine the timing and magnitude of fracture risk associated with antidepressant use.

Main Methods:

• Review of existing literature and epidemiological data on antidepressant use and fracture incidence.
• Comparative analysis of fracture risk across various antidepressant classes, including TCAs and SSRIs.
• Consideration of potential confounding factors, such as indication for treatment and fall risk.

Main Results:

• Selective serotonin reuptake inhibitors (SSRIs) appear to be associated with an increased fracture risk as a class effect, with an early increase noted within 14 days of initiation, possibly linked to falls.
• Amitriptyline, a tricyclic antidepressant (TCA), showed an association with increased fracture risk, likely due to an elevated risk of falls.
• Other antidepressant groups did not demonstrate a consistent association with fractures, though some showed a slight early increase in risk.

Conclusions:

• SSRIs and amitriptyline (a TCA) may pose a small but significant increased risk of fractures, with falls being a likely contributing factor.
• The overall impact on fracture risk across antidepressant classes appears modest, with limited differences between specific preparations.
• Confounding by indication, where depression itself may increase fracture risk, must be considered in interpreting these findings.